[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_MaterialEventDisclosureGeneralAbstract|
Material Event Disclosure General
oda_UpdateAnnouncementFlag|
Update Notification Flag
Hayır (No)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
-
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

-Unofficial Translation-

The registration processes of our products named Genbutrol 15 mmol/15 mL and Genbutrol 7.5 mmol/7.5 mL containing the active substance "Gadobutrol Monohydrate", which are produced in our GEN production facilities and used for diagnosis in magnetic resonance imaging systems, have been completed in our country.

It is aimed that the contribution of our products, whose licensing process has been completed, to the sales of our Company will be a total of 155,000 boxes and approximately TL 41,000,000 for 2022, a total of 186,000 boxes and approximately TL 59,000,000 for 2023, and a total of 223,200 boxes and approximately TL 85,000,000 for 2024.

With our products registration process of which has been completed, the scope of our company's product range and patient-oriented solutions has been expanded.